openPR Logo
Press release

The TIL-based therapies market is projected to be worth over USD 4.3 billion, by 2030, claims Roots Analysis

12-29-2021 05:53 AM CET | Health & Medicine

Press release from: Roots Analysis

The TIL-based therapies market is projected to be worth over USD

Driven by the potential to confer sustained therapeutic effects and thereby, facilitate prolonged periods of remission, TIL-based therapies have received significant financial support, and promising leads are poised to soon achieve blockbuster status

Roots Analysis has announced the addition of “TIL-based Therapies Market, 2021-2030” report to its list of offerings.

Given the frequently reported inadequacies of conventional cancer therapies and the growing need for personalized medicine, there is a marked surge in the demand for TIL-based therapies. In addition, the clinical success in this domain is likely to draw in investments that will support ongoing and anticipated therapy development initiatives.

To order this 255+ page report, which features 90+ figures and 100+ tables, please visit

Key Market Insights

Over 80 TIL-based therapies are currently under development
Close to 55% of the aforementioned candidates are being evaluated in clinical stages (phase I/II and above), while more than 20% therapies are in preclinical and discovery stages. Examples of late-stage clinical candidates include CCRT+TIL, Lifileucel, LTX-315 and TILs, and IOV-2001 and LN-145.

More than 80% pipeline candidates are presently being developed to target solid tumors
T-cell immunotherapy developers were observed to be primarily focused on the treatment of different oncological indications. It is worth noting that 17% pipeline candidates are being developed for the treatment of both hematological and solid tumors.

Partnership activity within this domain has increased at a CAGR of 45%, between 2011 and 2020
The maximum partnerships related to TIL-based therapies were inked in the period 2017-2019. Majority of partnership deals signed within this domain were R&D agreements (33%), followed by technology licensing (20%) and manufacturing (15%) agreements.

Over USD 2 billion has been invested by both private and public investors, across 30 instances
It is important to mention that, between 2013 and 2020, majority of the funding amount was raised through other equity financing elements (33%), venture capital rounds (30%) and secondary offerings (20%).

This market is anticipated to grow at a CAGR of 60.6%, during the period 2021-2030
Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and likely approval of some advanced stage therapy candidates. Further, North America (primarily the US) and Europe are expected to capture over 90% of the market share (in terms of sales-based revenues) by 2030.

To request a sample copy / brochure of this report, please visit

Key Questions Answered
 What are the prevalent R&D trends related to TIL-based therapies?
 Who are the leading industry and non-industry players engaged in the development of TIL-based therapies?
 What challenges are commonly faced by stakeholders engaged in this domain?
 Who are the key investors in this domain?
 Who are the key opinion leaders / experts engaged in this upcoming field of therapeutics?
 Which types of partnership models are commonly adopted by industry stakeholders?
 Which regions are key contract manufacturing hubs for TIL-based therapies?
 Which factors are likely to influence the evolution of this upcoming market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The USD 4.3+ billion (by 2030) financial opportunity within the TIL-based therapies market has been analyzed across the following segments:

 Target Indication
 Acute Lymphoblastic Leukemia
 Melanoma
 Others

 Key Players

 Key Geographical Regions
 North America
 Europe
 Asia Pacific

The research includes brief profiles, featuring an overview of the company, its financial information (if available), details related to its product(s), highlighting type of therapy and current development status, technology portfolio (if available), recent developments and manufacturing capabilities.
 Cellular Biomedicine Group
 Iovnace Biotherapeutics
 Lytix Biopharma
 Phio Pharmaceuticals

For additional details, please visit or email

You may also be interested in the following titles:
1. Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030
2. CAR-T Cell Therapies Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
3. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
4. Cell and Gene Therapy CROs Market: Industry Trends and Global Forecasts (2nd Edition), 2021-2030
5. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030

Contact Details
Ben Johnson
+1 (415) 800 3415

Roots Analysis

30.65, A 430, Bestech Business Towers,, Sector 66, Sahibzada Ajit Singh Nagar, Punjab 160066

We specialise in analysing areas which have lacked quality research so far or require more focussed understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The TIL-based therapies market is projected to be worth over USD 4.3 billion, by 2030, claims Roots Analysis here

News-ID: 2512841 • Views: 114

More Releases from Roots Analysis

Novel Drug Reconstitution Systems Market, 2021-2030
In 2018, seven out of ten top-selling prescription medicines were biologics. The liquid formulations of biologics are not much stable and tend to lose efficacy with time due to the changes in their pharmacokinetic and pharmacodynamic properties. Therefore, lyophilization of such drugs is essential before their storage. Around 50% of the biologics intended for parenteral administration are available in lyophilized form, which require reconstitution before administration. To Request for sample -
Squamous Non-small Cell Lung Cancer Market, 2021-2031 by Roots Analysis
Advances in molecular biology and tumor immunology have enabled the development of NSCLC targeting therapies, which have the ability to impede cancer growth by altering chemical reactions associated with oncogenic driver mutations Roots Analysis has announced the addition of “Squamous Non-small Cell Lung Cancer Market, 2021-2031” report to its list of offerings. Success of approved squamous non-small cell lung cancer therapies, such as Keytruda®, Opdivo® and Portrazza®, has resulted in a
The novel ocular drug delivery devices market is projected to grow at a CAGR of …
The delivery of drugs in ocular regions is known to be considerably more challenging; several pharmaceutical companies are actively undertaking initiatives to identify novel approaches for safe and efficient administration of therapies to eyes Roots Analysis has announced the addition of the “Novel Ocular Drug Delivery Devices Market, 2021 – 2030” report to its list of offerings. Over the years, a number of companies have developed several novel and advanced drug
The progressive supranuclear palsy (PSP) therapies market, is anticipated to gro …
The exact cause of this rare disorder, which affects 5-17 in 100,000 people, is unknown; however, a complex interplay between different risk factors, including age, genetics and environment, is likely to contribute to the onset of this rare tauopathy London Roots Analysis has announced the addition of “Progressive Supranuclear Palsy Therapies Market, 2021-2030” report to its list of offerings. Presently, there is no cure for PSP and the effectiveness of prescribed generic

All 5 Releases

More Releases for USD

$100,000,000 USD job contract for travel - $3,000,000 USD referral commission.
Khoja Consultants invites companies, teams or venture capitalists for a $100,000,000 USD contract for travel. The selected company will be providing all accommodations and expenses for a 6-month long business trip around the world. Khoja Consultants expects five-star treatment including close security with private planes, hotels, secured vehicles and helicopters if necessary. More details on the job contract and application are provided at - There is a $3,000,000
Polyurethane Dispersions Market worth USD 2.04 Billion USD by 2020
The report " Polyurethane Dispersions Market by Type (Water-Based Polyurethane Dispersions and Solvent-Based Polyurethane Dispersions), by Application (Coatings, Adhesives & Sealants, Synthetic Leather Production, Fiber Glass Sizing, and Others) - Trends & Forecasts to 2020", The global polyurethane dispersions market is projected to reach USD 2.04 Billion by 2020 at a CAGR of 6.8% between 2015 and 2020. This growth is fueled by the high potential from the textile and
Retail Analytics Market worth USD 5.1 Billion USD by 2020
According to a new market research report "Retail Analytics Market by Business Function (Marketing and Customer Analytics, Merchandizing and In-Store Analytics, Supply Chain Analytics, Strategy and Planning), by Type, by Solutions and by Services - Global Forecast and Analysis to 2020", defines and segments the global retail analytics market on the basis of business function, solutions, services, deployment types, and regions along with providing an in-depth analysis and market size
Metabolomics Market USD 1.24 Billion by 2020
The global metabolomics market is estimated to reach USD 1.24 Billion in 2020, growing at a CAGR of 15.6% from 2016 to 2020, according to a market research report Metabolomics Market 2013-2020, published by iHealthcareAnalyst, Inc. Visit the Metabolomics Market 2013-2020 report at Metabolomics is the scientific study of chemical processes involving metabolites, whereas metabolome represents the collection of all metabolites in a biological cell, tissue, organ or organism, which
Radiopharmaceuticals Market USD 350 Million by 2020
Radiopharmaceuticals Market 2013-2020 report estimates the global radiopharmaceuticals market to reach nearly USD 350 Million in 2020, at a CAGR of 4.9% from 2016 to 2020 - iHealthcareAnalyst, Inc. Visit the Radiopharmaceuticals Market 2013-2020 report Medicinal radiocompounds or radiopharmaceuticals are a group of pharmaceutical drugs which have radioactivity and they can be used as diagnostic and therapeutic agents. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers
Orthobiologics Market USD 5.8 Billion by 2020
Orthobiologics Market 2013-2020 report estimates the global orthobiologics market to reach nearly USD 5.8 Billion in 2020, at a CAGR of 6.2% from 2016 to 2020 - iHealthcareAnalyst, Inc. Visit the Orthobiologics Market 2013-2020 report The global orthobiologics market report provides market size (Revenue USD Million 2013 to 2020), market share and forecasts growth trends (CAGR%, 2016 to 2020). The global orthobiologics market segmentation is based on product types (allograft, bone